MCID: LKM061
MIFTS: 80

Leukemia, Acute Myeloid

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid 57 38
Acute Myeloid Leukemia 38 12 76 53 75 37 29 6 43 15
Leukemia, Acute Myelogenous 57 75 13 40
Leukemia, Acute Myeloid, Susceptibility to 57 29 6
Acute Undifferentiated Leukemia 59 55 73
Acute Myeloblastic Leukemia 12 76 75
Acute Myelogenous Leukemia 12 76 53
Acute Biphenotypic Leukemia 59 73
Leukemia, Myelocytic, Acute 12 73
Acute Myelocytic Leukemia 76 75
Leukemia, Myeloid, Acute 44 40
Aml 57 75
Acute Myeloid Leukaemia with Myelodysplasia-Related Features 59
Acute Myeloid Leukemia, Minimal Differentiation, Fab M0 59
Leukemia, Acute Myeloid, Reduced Survival in, Somatic 57
Acute Myeloid Leukemia with Cebpa Somatic Mutations 59
Acute Myeloid Leukemia with Multilineage Dysplasia 59
Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic 57
Aml with Myelodysplasia-Related Features 59
Pure Familial Acute Myeloid Leukemia 59
Leukemia, Acute Myeloid, Somatic 57
Aml with Cebpa Somatic Mutations 59
Inherited Acute Myeloid Leukemia 59
Acute Non-Lymphoblastic Leukemia 75
Acute Myeloid Leukemia, Somatic 57
Aml with Multilineage Dysplasia 59
Acute Non-Lymphocytic Leukemia 75
Aml - Acute Myeloid Leukemia 12
Bilineal Acute Leukemia 59
Pure Familial Aml 59
Inherited Aml 59
Familial Aml 59

Characteristics:

Orphanet epidemiological data:

59

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
leukemia, acute myeloid:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 601626
Disease Ontology 12 DOID:9119
ICD9CM 35 205.0
MeSH 44 D015470
NCIt 50 C27753 C3171
ICD10 via Orphanet 34 C92.0 C92.8 C95.0
UMLS via Orphanet 74 C1292773 C0023464 C0280141 more
MESH via Orphanet 45 D015456
KEGG 37 H00003
SNOMED-CT via HPO 69 263681008

Summaries for Leukemia, Acute Myeloid

MedlinePlus : 43 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Bleeding under the skin Weakness or feeling tired Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to acute myeloblastic leukemia without maturation and acute myeloblastic leukemia with maturation, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Acute myeloid leukemia and Transcriptional misregulation in cancer. The drugs Leukine and Lynparza have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute myeloid leukemia and Reduced mammosphere formation

Disease Ontology : 12 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases : 53 Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inheritedsyndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy.

UniProtKB/Swiss-Prot : 75 Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia : 76 Acute myeloblastic leukemia is a form of myeloid leukemia affecting... more...

Description from OMIM: 601626

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Acute Myeloid Leukemia with T(9;11)(p22;q23) Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 acute myeloblastic leukemia without maturation 36.2 FLT3 NPM1
2 acute myeloblastic leukemia with maturation 36.1 FLT3 KIT NPM1
3 leukemia 35.2 CEBPA ETV6 FLT3 JAK2 KIT NPM1
4 acute promyelocytic leukemia 35.2 CEBPA FLT3 NPM1 NRAS RUNX1
5 platelet disorder, familial, with associated myeloid malignancy 35.1 ETV6 RUNX1
6 acute leukemia 34.7 CEBPA ETV6 FLT3 JAK2 KIT MLLT10
7 cytogenetically normal acute myeloid leukemia 34.3 CEBPA FLT3 IDH1 NPM1
8 myeloid leukemia 34.3 CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
9 myelodysplastic syndrome 33.0 CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
10 leukemia, acute lymphoblastic 32.0 ETV6 FLT3 PICALM RUNX1
11 lymphoblastic leukemia 31.8 ETV6 FLT3 JAK2 RUNX1
12 myeloid sarcoma 31.8 FLT3 KIT NPM1
13 acute non lymphoblastic leukemia 12.5
14 acute biphenotypic leukemia 12.4
15 hematologic cancer 12.1 ETV6 FLT3 GATA2 JAK2 KIT MLLT10
16 core binding factor acute myeloid leukemia 11.9 CEBPA FLT3 JAK2 KIT KRAS NRAS
17 aml with myelodysplasia-related features 11.9
18 leukemia, chronic myeloid 11.9 ETV6 FLT3 GATA2 JAK2 KIT NRAS
19 chronic myelomonocytic leukemia 11.9 DNMT3A ETV6 FLT3 JAK2 KIT RUNX1
20 juvenile myelomonocytic leukemia 11.8 DNMT3A FLT3 JAK2 KRAS NRAS RUNX1
21 bone marrow cancer 11.8 ETV6 FLT3 JAK2 KIT RUNX1
22 precursor t-cell acute lymphoblastic leukemia 11.7 ETV6 FLT3 MLLT10 NUP214 PICALM
23 wilms tumor 1 11.7 CEBPA FLT3 KRAS NPM1 TERT
24 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.7 CEBPA FLT3 KIT RUNX1
25 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 11.7 ETV6 FLT3 KIT RUNX1
26 lung cancer susceptibility 3 11.7 DNMT3A IDH1 KRAS NRAS TERT
27 cell type cancer 11.7 IDH1 KIT KRAS NRAS
28 acral lentiginous melanoma 11.6 KIT NRAS TERT
29 lymphoid leukemia 11.6 ETV6 FLT3 JAK2
30 vulvar melanoma 11.6 KIT NRAS TERT
31 undifferentiated pleomorphic sarcoma 11.6 IDH1 KIT KRAS
32 mucosal melanoma 11.6 KIT NRAS TERT
33 congenital mesoblastic nephroma 11.5 ETV6 KIT NRAS
34 myelofibrosis 11.5 FLT3 IDH1 JAK2 KIT
35 aleukemic leukemia cutis 11.5 FLT3 NPM1 RUNX1
36 8p11 myeloproliferative syndrome 11.5 FLT3 KIT RUNX1
37 aplastic anemia 11.5 FLT3 GATA2 NRAS TERT
38 leukemia, acute lymphoblastic 3 11.4 ETV6 FLT3 RUNX1
39 differentiated thyroid carcinoma 11.4 ETV6 KRAS NRAS
40 b-cell childhood acute lymphoblastic leukemia 11.4 ETV6 RUNX1
41 acute leukemia of ambiguous lineage 11.3
42 cholangiocarcinoma 11.3 IDH1 KIT KRAS TERT
43 schimmelpenning-feuerstein-mims syndrome 11.3 KRAS NRAS
44 ovarian melanoma 11.3 KIT NRAS
45 cellular congenital mesoblastic nephroma 11.2 ETV6 NRAS
46 erythroleukemia, familial 11.2
47 megakaryocytic leukemia 11.1
48 medulloblastoma 11.1
49 neutrophilia, hereditary 11.1 FLT3 JAK2
50 aggressive digital papillary adenocarcinoma 11.0 KIT KRAS

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:



Diseases related to Leukemia, Acute Myeloid

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Symptoms via clinical synopsis from OMIM:

57
Heme:
familial acute myelogenous leukemia (aml)

Misc:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations


Clinical features from OMIM:

601626

Human phenotypes related to Leukemia, Acute Myeloid:

32
# Description HPO Frequency HPO Source Accession
1 acute myeloid leukemia 32 HP:0004808

UMLS symptoms related to Leukemia, Acute Myeloid:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CEBPA DNMT3A ETV6 KRAS NRAS NUP214

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.46 ETV6 FLT3 GATA2 JAK2 KIT KRAS
2 homeostasis/metabolism MP:0005376 10.4 CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
3 hematopoietic system MP:0005397 10.39 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
4 growth/size/body region MP:0005378 10.37 CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
5 mortality/aging MP:0010768 10.36 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
6 immune system MP:0005387 10.32 DNMT3A ETV6 FLT3 IDH1 JAK2 KIT
7 endocrine/exocrine gland MP:0005379 10.31 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
8 embryo MP:0005380 10.29 KRAS NPM1 NRAS NUP214 PICALM RUNX1
9 cardiovascular system MP:0005385 10.22 KRAS NPM1 NRAS RUNX1 CEBPA CHIC2
10 integument MP:0010771 10.16 CEBPA CHIC2 ETV6 JAK2 KIT KRAS
11 liver/biliary system MP:0005370 10.09 RUNX1 CEBPA GATA2 JAK2 KIT KRAS
12 neoplasm MP:0002006 10.07 CEBPA ETV6 FLT3 JAK2 KIT KRAS
13 normal MP:0002873 9.91 TERT CEBPA ETV6 GATA2 JAK2 KIT
14 no phenotypic analysis MP:0003012 9.87 CEBPA ETV6 FLT3 KIT KRAS NRAS
15 reproductive system MP:0005389 9.61 JAK2 KIT KRAS LPP TERT CEBPA
16 pigmentation MP:0001186 9.55 CHIC2 KIT KRAS NRAS PICALM
17 skeleton MP:0005390 9.32 FLT3 IDH1 JAK2 KIT KRAS NRAS

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Leukine 18 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
2
Lynparza 18 49 OLAPARIB AstraZeneca December 2014
3
Mylotarg 18 49 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
4
Neupogen 18 49 FILGRASTIM Amgen Approval April 1998

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 643)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
2
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
3
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
4
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
5
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
6
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
7
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
8
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
9
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
10
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
11
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
12
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
13
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
14
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
15
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
16
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
17
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
18
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
19
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 191732-72-6 216326
20
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
21
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
22
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171228-49-2 147912
23
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
24
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
25
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
26 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
28
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 5280795
29
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
30 Molgramostim Investigational Phase 4,Phase 3 99283-10-0
31
Aclarubicin Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57576-44-0 451415
32 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Gemtuzumab Phase 4,Phase 2,Phase 3,Phase 1
46 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
47 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2491)
# Name Status NCT ID Phase Drugs
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
4 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
7 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
8 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
9 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
10 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
11 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
12 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
13 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
14 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
15 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
16 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4 Cytarabine Dosage
17 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
18 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4 Mylotarg
19 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
20 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
21 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
22 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
23 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
24 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
25 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Recruiting NCT02027064 Phase 4 Interferon-alpha
26 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4 recombinant human thrombopoietin
27 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
28 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
29 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
30 A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
31 King's Invasive Aspergillosis Study II Not yet recruiting NCT02875743 Phase 4 Posaconazole
32 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
33 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
34 LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Terminated NCT01198054 Phase 4 Lenalidomide
35 the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3 Cyclosporin A,mycophenolate mofetil,Methotrexate
36 HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia Unknown status NCT01484171 Phase 3 idarubicin
37 A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Unknown status NCT01303796 Phase 3 Sapacitabine and decitabine;Decitabine
38 Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia Unknown status NCT02244658 Phase 3 rhTPO
39 Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
40 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3 Decitabine
41 Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) Unknown status NCT01145846 Phase 3 Cytarabine plus Daunorubicin [Arm II (AD regimen)]
42 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
43 Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia Unknown status NCT00224614 Phase 3
44 Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study Unknown status NCT00715637 Phase 3 Daunorubicin and Cytarabine;Amonafide and Cytarabine
45 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
46 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
47 Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
48 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
49 Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia Unknown status NCT02072811 Phase 3 DAC;CLAG;Consolidation, I HAM cycle;II Consolidation HiDAraC;Consolidation, III HiDAraC cycle
50 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia 29 CEBPA DNMT3A KRAS
2 Leukemia, Acute Myeloid, Susceptibility to 29

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

41
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells Affected by disease
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 4771)
# Title Authors Year
1
Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Adv</i>. 2017;2(4):444-453. ( 29618463 )
2018
2
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )
2018
3
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )
2018
4
Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. ( 29573577 )
2018
5
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )
2018
6
Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia. ( 29431568 )
2018
7
A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. ( 29452230 )
2018
8
Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. ( 29705537 )
2018
9
Editorial Comment to Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29869384 )
2018
10
MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. ( 29976747 )
2018
11
Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. ( 29168399 )
2018
12
High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. ( 28836868 )
2018
13
Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34a8_CD123a8_ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. ( 29439554 )
2018
14
Patient-reported outcomes in acute myeloid leukemia: Where are we now? ( 28888621 )
2018
15
A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. ( 29892549 )
2018
16
Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia. ( 29154208 )
2018
17
Regulation of Expression of CEBP Genes by Variably Expressed Vitamin D Receptor and Retinoic Acid Receptor I+ in Human Acute Myeloid Leukemia Cell Lines. ( 29966306 )
2018
18
Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia. ( 28540755 )
2018
19
Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. ( 29843224 )
2018
20
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. ( 29247780 )
2018
21
The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia. ( 28646564 )
2018
22
Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization. ( 29191655 )
2018
23
Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. ( 29928481 )
2018
24
Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review. ( 29661468 )
2018
25
Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. ( 29731877 )
2018
26
Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). ( 29978286 )
2018
27
Acute Progressive Visual Loss in a Case of Acute Myeloid Leukemia: Challenges in the Utility of Molecular Tests in Early Diagnose of Cytomegalovirus Retinitis. ( 29560000 )
2018
28
Therapy-related Acute Myeloid Leukemia After the Treatment of Primary Solid Cancer in Children: A Single-center Experience. ( 29200163 )
2018
29
Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. ( 29627222 )
2018
30
Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia. ( 29980537 )
2018
31
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). ( 28838276 )
2018
32
Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )
2018
33
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. ( 29321554 )
2018
34
<i>NPM1</i> Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction. ( 29129825 )
2018
35
Initial therapy for acute myeloid leukemia in older patients: principles of care. ( 28573900 )
2018
36
Nucleophosmin-1 regions associated with acute myeloid leukemia interact differently with lipid membranes. ( 29330024 )
2018
37
CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. ( 29976748 )
2018
38
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. ( 29119643 )
2018
39
Acute external otitis as debut of acute myeloid leukemia - A case and review of the literature. ( 29447882 )
2018
40
NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. ( 29866886 )
2018
41
Protracted Clonal Trajectory of a <i>JAK2</i> V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. ( 29854499 )
2018
42
Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. ( 29981272 )
2018
43
Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. ( 29933069 )
2018
44
Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature. ( 29428448 )
2018
45
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. ( 29692343 )
2018
46
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. ( 29097499 )
2018
47
Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29752743 )
2018
48
Identification of novel <i>MECOM</i> gene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review. ( 29572239 )
2018
49
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. ( 29449224 )
2018
50
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. ( 29487059 )
2018

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

75
# Symbol AA change Variation ID SNP ID
1 CEBPA p.His84Leu VAR_072677 rs28931590
2 JAK2 p.Lys607Asn VAR_032696 rs121912472
3 JAK2 p.Val617Phe VAR_032697 rs77375493
4 SETBP1 p.Gly870Ser VAR_063809 rs267607040
5 SETBP1 p.Ser854Ala VAR_069848
6 SETBP1 p.Gly870Arg VAR_069854
7 SETBP1 p.Ile871Ser VAR_069856

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

6
(show top 50) (show all 672)
# Gene Variation Type Significance SNP ID Assembly Location
1 ETV6 NM_001987.4(ETV6): c.226G> T (p.Glu76Ter) single nucleotide variant Pathogenic rs121434637 GRCh37 Chromosome 12, 11992136: 11992136
2 ETV6 NM_001987.4(ETV6): c.226G> T (p.Glu76Ter) single nucleotide variant Pathogenic rs121434637 GRCh38 Chromosome 12, 11839202: 11839202
3 ETV6 NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly) insertion Pathogenic rs587776710 GRCh37 Chromosome 12, 12043928: 12043929
4 ETV6 NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly) insertion Pathogenic rs587776710 GRCh38 Chromosome 12, 11890994: 11890995
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
11 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
12 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
13 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
14 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
15 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
16 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
17 KRAS NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly) duplication Pathogenic rs606231202 GRCh38 Chromosome 12, 25245356: 25245358
18 KRAS NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly) duplication Pathogenic rs606231202 GRCh37 Chromosome 12, 25398290: 25398292
19 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
20 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
21 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
22 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
23 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
24 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
25 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
26 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
27 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
28 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
29 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
30 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
31 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
32 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
33 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
34 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
35 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
36 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
37 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
38 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
39 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
40 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
41 NPM1 NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs) duplication Pathogenic rs587776806 GRCh38 Chromosome 5, 171410540: 171410543
42 NPM1 NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs) duplication Pathogenic rs587776806 GRCh37 Chromosome 5, 170837544: 170837547
43 NPM1 NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
44 NPM1 NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh37 Chromosome 5, 170837547: 170837548
45 NPM1 NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
46 NPM1 NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh37 Chromosome 5, 170837547: 170837548
47 NPM1 NM_002520.6(NPM1): c.863_864insCCTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
48 NPM1 NM_002520.6(NPM1): c.863_864insCCTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh37 Chromosome 5, 170837547: 170837548
49 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
50 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh38 Chromosome 9, 5073770: 5073770

Copy number variations for Leukemia, Acute Myeloid from CNVD:

7 (show top 50) (show all 491)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13336 1 1 124300000 Insertion Acute myeloid leukemia
2 13759 1 1 28000000 Deletion Acute myeloid leukemia
3 14790 1 110122000 110569000 Gain or loss Acute myeloid leukemia
4 17466 1 142902432 245422360 Duplication Acute myeloid leukemia
5 18096 1 143961000 247125000 Gain or loss Acute myeloid leukemia
6 20826 1 154656757 154656845 Amplification Acute myeloid leukemia
7 24589 1 182359000 182787000 Loss Acute myeloid leukemia
8 26098 1 197094625 197094734 Amplification Acute myeloid leukemia
9 26100 1 197094796 197094905 Amplification Acute myeloid leukemia
10 27148 1 204981000 205049000 Gain or loss Acute myeloid leukemia
11 27263 1 206041820 206041907 Amplification Acute myeloid leukemia
12 27859 1 214500000 224100000 Deletion Acute myeloid leukemia
13 28491 1 222606000 222909000 Gain or loss Acute myeloid leukemia
14 29341 1 230606000 230646000 Gain or loss Acute myeloid leukemia
15 32943 1 40683565 40683656 Amplification Acute myeloid leukemia
16 32944 1 40686494 40686582 Amplification Acute myeloid leukemia
17 33084 1 42072000 42456000 Gain or loss Acute myeloid leukemia
18 35033 1 5913000 7696000 Gain or loss Acute myeloid leukemia
19 35608 1 65296705 65296779 Amplification Acute myeloid leukemia
20 35769 1 67074000 69951000 Gain or loss Acute myeloid leukemia
21 36085 1 71305902 71305987 Amplification miR-186 Acute myeloid leukemia
22 38187 10 1 6700000 Insertion IL15RA Acute myeloid leukemia
23 38188 10 1 6700000 Insertion PRKCQ Acute myeloid leukemia
24 38677 10 104186259 104186331 Deletion Acute myeloid leukemia
25 38804 10 105144000 105144148 Deletion Acute myeloid leukemia
26 39144 10 110889374 110889450 Deletion Acute myeloid leukemia
27 39902 10 122017230 122017301 Deletion let-7a-2 Acute myeloid leukemia
28 41668 10 21893278 22027081 Loss MLLT10 Acute myeloid leukemia
29 41990 10 27075530 27189965 Translate SSH3BP1 Acute myeloid leukemia
30 43278 10 46100000 49900000 Copy number GDF10 Acute myeloid leukemia
31 44445 10 57165247 57165335 Deletion Acute myeloid leukemia
32 44874 11 64658609 64658718 Deletion miR-192 Acute myeloid leukemia
33 45369 10 70521000 135283000 Gain Acute myeloid leukemia
34 47681 10 96486000 100815000 Loss Acute myeloid leukemia
35 49592 11 108316750 133951370 Triplication Acute myeloid leukemia
36 50142 11 114500000 121200000 Copy number MLL Acute myeloid leukemia
37 50190 11 115400000 120700000 Insertion DDX6 Acute myeloid leukemia
38 50191 11 115400000 120700000 Insertion ETS1 Acute myeloid leukemia
39 50192 11 115400000 120700000 Insertion FLI1 Acute myeloid leukemia
40 50193 11 115400000 120700000 Insertion MLL Acute myeloid leukemia
41 50261 11 116297361 116448564 Loss Acute myeloid leukemia
42 50346 11 117203762 118563610 Amplification Acute myeloid leukemia
43 50385 11 117603158 117860329 Duplication Acute myeloid leukemia
44 50437 11 117820656 117856311 Gain MLL Acute myeloid leukemia
45 50640 11 118585028 127052111 Deletion Acute myeloid leukemia
46 51468 11 126537000 130235000 Gain Acute myeloid leukemia
47 51512 11 127394408 133951311 Amplification Acute myeloid leukemia
48 52810 11 2016406 2019065 Methylation H19 Acute myeloid leukemia
49 53744 11 32409321 32457081 Mutation WT1 Acute myeloid leukemia
50 54217 11 39671000 39746000 Loss Acute myeloid leukemia

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

37
# Name Kegg Source Accession
1 Acute myeloid leukemia hsa05221
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.74 FLT3 JAK2 KIT KRAS NRAS TERT
2
Show member pathways
12.54 CEBPA FLT3 KIT KRAS NRAS RUNX1
3 12.28 CEBPA GATA2 JAK2 KIT RUNX1
4 12.28 CEBPA FLT3 JAK2 KIT KRAS NRAS
5
Show member pathways
12.26 FLT3 JAK2 KRAS NRAS
6 12.03 CEBPA ETV6 FLT3 RUNX1
7 11.88 FLT3 JAK2 KIT NPM1
8
Show member pathways
11.78 JAK2 KRAS NRAS
9 11.73 JAK2 KRAS NRAS
10 11.58 CEBPA KIT NRAS
11 11.48 GATA2 NPM1 TERT
12
Show member pathways
11.47 JAK2 KRAS NRAS
13
Show member pathways
11.38 FLT3 KIT KRAS NRAS
14 11.14 JAK2 KRAS NRAS
15 10.83 FLT3 IDH1 KIT KRAS NRAS
16 10.78 DNMT3A ETV6 FLT3
17 10.64 KRAS NRAS

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 CEBPA DNMT3A GATA2 JAK2 MLLT10 NPM1
2 nucleus GO:0005634 9.8 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
3 focal adhesion GO:0005925 9.02 JAK2 KRAS LPP NPM1 NUP214

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.83 FLT3 JAK2 KIT KRAS NPM1
2 MAPK cascade GO:0000165 9.76 JAK2 KIT KRAS NRAS
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.54 FLT3 JAK2 KIT
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 FLT3 JAK2 KIT
5 positive regulation of MAP kinase activity GO:0043406 9.43 FLT3 KIT KRAS
6 hematopoietic stem cell proliferation GO:0071425 9.4 ETV6 RUNX1
7 cytokine-mediated signaling pathway GO:0019221 9.35 CEBPA FLT3 JAK2 KIT KRAS
8 myeloid progenitor cell differentiation GO:0002318 9.16 FLT3 KIT
9 hemopoiesis GO:0030097 9.02 FLT3 GATA2 KIT PICALM RUNX1

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
2 protein homodimerization activity GO:0042803 9.43 CEBPA FLT3 IDH1 KIT NPM1 TERT

Sources for Leukemia, Acute Myeloid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....